Biotech | September 07, 2022
Lonza and Touchlight collaborate on end-to-end mRNA offering
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Lutio has the potential to offer significant cost savings when available to UK patients.
3D CMOS chip for connecting electroactive tissues and organoids to software
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
